Alveolar rhabdomyosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Alveolar rhabdomyosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study of Personalized Peptide Vaccine with PERVI-FUS, PERVI-NEO, and 11902A for Children and Young Adults with Metastatic Fusion-Driven Sarcomas https://clinicaltrials.eu/trial/study-of-personalized-peptide-vaccine-with-pervi-fus-pervi-neo-and-11902a-for-children-and-young-adults-with-metastatic-fusion-driven-sarcomas/ Wed, 29 Apr 2026 14:23:09 +0000 https://clinicaltrials.eu/trial/study-of-personalized-peptide-vaccine-with-pervi-fus-pervi-neo-and-11902a-for-children-and-young-adults-with-metastatic-fusion-driven-sarcomas/ This clinical trial is focused on studying certain types of cancer known as fusion-driven sarcomas. These are rare cancers that can spread to other parts of the body, a process known as metastasis. The specific types of sarcomas being studied include Ewing sarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma. The trial is designed for patients who have already undergone standard treatments and are in a state of either complete or partial remission, meaning the cancer has either disappeared or reduced in size.

The treatment being tested in this study is an IPX vaccine, which is an emulsion for injection. This vaccine is made up of specific proteins, including PERVI-FUS, PERVI-NEO, and 11902A. The purpose of the study is to see if this vaccine can help the body’s immune system, particularly T-cells, to respond to the cancer. T-cells are a type of white blood cell that play a crucial role in the immune response. The study will compare the effects of the vaccine to a placebo, which is a substance with no active ingredients.

Participants in the study will receive the vaccine over a period of time, with the maximum treatment period being 113 days. The study will monitor the participants’ immune response to the vaccine, as well as their overall health and quality of life during the treatment. The primary goal is to determine if the vaccine can successfully induce a T-cell response without causing unacceptable side effects. The study will also look at other factors, such as the participants’ event-free survival and overall survival at 180 days after the start of the study.

]]>